50419 0403 01 Splimage30 9a194d0a
Safyral Kit
Product Images NDC 50419-403
View Photos of Packaging, Regulatory Labels, and Product Appearance
Product Visual Gallery
This gallery contains 14 technical images submitted to the FDA as part of the official labeling for Safyral (NDC 50419-403). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.
As provided by Bayer Healthcare Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.
Product Images & Figures Index
50419 0403 01 Splimage30 9d194eba
Structural Formula (81e02158 706e 4e03 88c7 1990a0d6cd9d 03)
Figure 3 (81e02158 706e 4e03 88c7 1990a0d6cd9d 04)
This is a chart displaying the levels of plasma folate (in nmol/L) over time, with values ranging from 0 to 100. The chart compares 196 individuals who took a medication called YAZ+levomefolate calcium to 66 individuals who took only YAZ. Data was collected at various time points over the course of 22 weeks.*
Figure 4 (81e02158 706e 4e03 88c7 1990a0d6cd9d 05)
Figure 5 (81e02158 706e 4e03 88c7 1990a0d6cd9d 06)
Figure 6 (81e02158 706e 4e03 88c7 1990a0d6cd9d 07)
Pregnancy Chart (81e02158 706e 4e03 88c7 1990a0d6cd9d 08)
This text is discussing different methods of birth control, including the number of pregnancies per 100 women for each method. It lists various options such as injections, intrauterine devices, sterilization, birth control pills, condoms, diaphragms, and natural methods like abstaining during fertile days or withdrawal.*
Blister Image (81e02158 706e 4e03 88c7 1990a0d6cd9d 09)
Likelihood Of Developing A Serious Blood Clot (81e02158 706e 4e03 88c7 1990a0d6cd9d 10)
This text provides a table showing the ranges of the number of women with blood clots per 10,000 women years for different conditions, including non-pregnant, non-COC user, COC user, pregnancy, and postpartum. The pregnancy data is based on actual duration of pregnancy in reference studies and the assumption that pregnancy lasts for nine months, with a rate of 7 to 27 per 10,000 WY.*
Trade Carton.jpg (81e02158 706e 4e03 88c7 1990a0d6cd9d 11)
Image 01
This appears to be a list of different studies and their corresponding hazard ratio, rate ratio, or odds ratio. The studies mentioned include Ingenix, EURAS, LASS, a FDA-funded study, a Danish study, a Danish re-analysis, MEGA, a German case-control study, and GPRD. There is also mention of different types of studies including prospective and retrospective cohort studies, case-control studies, and non-fatal idiopathic cases. It is difficult to provide a more specific description as the text seems to be missing important information and context.*
Image 02
This text appears to be a table showing ranges of values for non-pregnant women, non-COC users, COC users, pregnancy, and postpartum. It also includes information on the number of women with a blood clot out of 10,000 women years, with a note indicating that the pregnancy data is based on actual duration of pregnancy in the reference studies, and that the rate is 7 o 27 per 10,000 WY assuming a pregnancy duration of nine months.*
Image 03
This text appears to be a list of relevant studies on the risk of breast cancer associated with combined oral contraceptives. Each study is identified by its name, the year it was conducted, and the lead author. The text also includes some numbers, possibly representing risk estimates or statistical confidence intervals, but without further context, it is not clear what they mean.*
* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.
